Induction of heat shock proteins in differentiated human neuronal cells following co-application of celastrol and arimoclomol

Cell Stress and Chaperones

Volumn 21, Issue 5, 2016, Pages 837-848

  Deane, Catherine A S ^a   Brown, Ian R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Arimoclomol; Celastrol; Heat shock; HSPA1A (Hsp70 1); HSPA6 (Hsp70B ); Human SH SY5Y neuronal cells

Indexed keywords

ARIMOCLOMOL; BINDING PROTEIN; CELASTROL; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70B; HEAT SHOCK PROTEIN 90 ALPHA; HEAT SHOCK TRANSCRIPTION FACTOR 1; HEME OXYGENASE 1; UNCLASSIFIED DRUG; HYDROXYLAMINE; TRIPTERINE; TRITERPENE;

ARTICLE; CELL STRUCTURE; CELL VIABILITY; COMPARATIVE STUDY; DEGENERATIVE DISEASE; DRUG EFFECT; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM INFLAMMATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN INDUCTION; PROTEIN MISFOLDING; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HEAT SHOCK RESPONSE; METABOLISM; NERVE CELL; TRANSCRIPTION INITIATION;

CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; HEAT-SHOCK PROTEINS; HEAT-SHOCK RESPONSE; HUMANS; HYDROXYLAMINES; NEURONS; TRANSCRIPTIONAL ACTIVATION; TRITERPENES;

EID: 84976274009     PISSN: 13558145     EISSN: 14661268     Source Type: Journal    
DOI: 10.1007/s12192-016-0708-2     Document Type: Article

References (93)

1. Abbott A (2002) Neurologists strike gold in drug screen effort. Nature 417:109. doi:10.1038/417109a
2. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C (2001) Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 25:1341–1357. doi:10.1016/S0278-5846(01)00192-0
3. Amor S, Puentes F, Baker D, van der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129:154–169. doi:10.1111/j.1365-2567.2009.03225.x
4. Amor S, Peferoen LA, Vogel DY, Breur M, van der Valk P, Baker D, van Noort JM (2014) Inflammation in neurodegenerative diseases—an update. Immunology 142:151–166. doi:10.1111/imm.12233
5. Asea AA, Brown IR (2008) Heat shock proteins and the brain: implications for neurodegenerative diseases and neuroprotection. Springer Science+Business Media B.V. pp. 1–373
6. Batulan Z, Taylor DM, Aarons RJ, Minotti S, Doroudchi MM, Nalbantoglu J, Durham HD (2006) Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis. Neurobiol Dis 24:213–225. doi:10.1016/j.nbd.2006.06.017
7. Bechtold DA, Brown IR (2000) Heat shock proteins Hsp27 and Hsp32 localize to synaptic sites in the rat cerebellum following hyperthermia. Brain Res Mol Brain Res 75:309–320. doi:10.1016/S0169-328X(99)00323-X
8. Bechtold DA, Rush SJ, Brown IR (2000) Localization of the heat-shock protein Hsp70 to the synapse following hyperthermic stress in the brain. J Neurochem 74:641–646
9. Brown IR (2008) Heat Shock Proteins at the synapse: implications for functional protection of the nervous system. In: Brown IR, Asea AA (eds) Heat shock proteins and the brain: implications for neurodegenerative diseases and neuroprotection, vol 3. Springer Science+Business Media B.V., pp 239–254
10. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51:347–372. doi:10.1021/jm7009364
11. Chen S, Brown IR (2007) Translocation of constitutively expressed heat shock protein Hsc70 to synapse-enriched areas of the cerebral cortex after hyperthermic stress. J Neurosci Res 85:402–409. doi:10.1002/jnr.21124
12. Chen Y, Wang B, Liu D, Li JJ, Xue Y, Sakata K, Zhu LQ, Heldt SA, Xu H, Liao FF (2014) Hsp90 chaperone inhibitor 17-AAG attenuates A beta-induced synaptic toxicity and memory impairment. J Neurosci 34(7):2464--2470. doi:10.1523/JNEUROSCI.0151-13.2014
13. Cheung YT, Lau WK, Yu MS, Lai CS, Yeung SC, So KF, Chang RC (2009) Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research. Neurotoxicology 30:127–135. doi:10.1016/j.neuro.2008.11.001
14. Choi BS, Kim H, Lee HJ, Sapkota K, Park SE, Kim S, Kim SJ (2014) Celastrol from ‘Thunder God Vine’ protects SH-SY5Y cells through the preservation of mitochondrial function and inhibition of p38 MAPK in a rotenone model of Parkinson’s disease. Neurochem Res 39:84–96. doi:10.1007/s11064-013-1193-y
15. Chow AM, Brown IR (2007) Induction of heat shock proteins in differentiated human and rodent neurons by celastrol. Cell Stress Chaperones 12:237–244
16. Chow AM, Mok P, Xiao D, Khalouei S, Brown IR (2010) Heteromeric complexes of heat shock protein 70 (HSP70) family members, including Hsp70B’, in differentiated human neuronal cells. Cell Stress Chaperones 15:545–553. doi:10.1007/s12192-009-0167-0
17. Chung WS, Welsh CA, Barres BA, Stevens B (2015) Do glia drive synaptic and cognitive impairment in disease? Nat Neurosci 18:1539–1545. doi:10.1038/nn.4142
18. Cleren C, Calingasan NY, Chen J, Beal MF (2005) Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J Neurochem 94:995–1004. doi:10.1111/j.1471-4159.2005.03253.x
19. Dekker SL, Kampinga HH, Bergink S (2015) DNAJs: more than substrate delivery to HSPA. Front Mol Biosci 2:35. doi:10.3389/fmolb.2015.00035
20. DeKosky ST, Marek K (2003) Looking backward to move forward: early detection of neurodegenerative disorders. Science 302:830–834. doi:10.1126/science.1090349
21. Dunkel P, Chai CL, Sperlagh B, Huleatt PB, Matyus P (2012) Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases, and amyotrophic lateral sclerosis. Expert Opin Investig Drugs 21:1267–1308. doi:10.1517/13543784.2012.703178
22. Fan CY, Lee S, Cyr DM (2003) Mechanisms for regulation of Hsp70 function by Hsp40. Cell Stress Chaperones 8:309–316
23. Faust K, Gehrke S, Yang Y, Yang L, Beal MF, Lu B (2009) Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson’s disease. BMC Neurosci 10:109. doi:10.1186/1471-2202-10-109
24. Gao HM, Hong JS (2008) Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 29:357–365. doi:10.1016/j.it.2008.05.002
25. Genc B, Ozdinler PH (2013) Moving forward in clinical trials for ALS: motor neurons lead the way please. Drug Discov Today. doi:10.1016/j.drudis.2013.10.014
26. Gifondorwa DJ et al (2007) Exogenous delivery of heat shock protein 70 increases lifespan in a mouse model of amyotrophic lateral sclerosis. J Neurosci 27:13173–13180. doi:10.1523/JNEUROSCI.4057-07.2007
27. Goloubinoff P, De Los RP (2007) The mechanism of Hsp70 chaperones: (entropic) pulling the models together. Trends Biochem Sci 32:372–380. doi:10.1016/j.tibs.2007.06.008
28. Hargitai J et al (2003) Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun 307:689–695. doi:10.1016/S0006-291X(03)01254-3
29. Heemskerk J, Tobin AJ, Bain LJ (2002) Teaching old drugs new tricks. Meeting of the Neurodegeneration Drug Screening Consortium, 7–8 April 2002, Washington, DC, USA Trends Neurosci 25:494–496 doi:10.1016/S0166-2236(02)02236-1
30. Hong S, Dissing-Olesen L, Stevens B (2016) New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol 36:128–134. doi:10.1016/j.conb.2015.12.004
31. Hoshino T et al (2011) Suppression of Alzheimer’s disease-related phenotypes by expression of heat shock protein 70 in mice. J Neurosci 31:5225–5234. doi:10.1523/JNEUROSCI.5478-10.2011
32. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148:1204–1222. doi:10.1016/j.cell.2012.02.040
33. Jacobs S, Lie DC, DeCicco KL, Shi Y, DeLuca LM, Gage FH, Evans RM (2006) Retinoic acid is required early during adult neurogenesis in the dentate gyrus. Proc Natl Acad Sci U S A 103:3902–3907. doi:10.1073/pnas.0511294103
34. Jantas D, Roman A, Kusmierczyk J, Lorenc-Koci E, Konieczny J, Lenda T, Lason W (2013) The extent of neurodegeneration and neuroprotection in two chemical in vitro models related to Parkinson’s disease is critically dependent on cell culture conditions. Neurotox Res 24:41–54. doi:10.1007/s12640-012-9374-z
35. Jung HW, Chung YS, Kim YS, Park YK (2007) Celastrol inhibits production of nitric oxide and proinflammatory cytokines through MAPK signal transduction and NF-kappaB in LPS-stimulated BV-2 microglial cells. Exp Mol Med 39:715–721. doi:10.1038/emm.2007.78
36. Kalmar B, Novoselov S, Gray A, Cheetham ME, Margulis B, Greensmith L (2008) Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem 107:339–350. doi:10.1111/j.1471-4159.2008.05595.x
37. Kalmar B, Lu CH, Greensmith L (2014) The role of heat shock proteins in amyotrophic lateral sclerosis: the therapeutic potential of Arimoclomol. Pharmacol Ther 141:40–54. doi:10.1016/j.pharmthera.2013.08.003
38. Karunanithi S, Brown IR (2015) Heat shock response and homeostatic plasticity. Front Cell Neurosci 9:68. doi:10.3389/fncel.2015.00068
39. Karunanithi S, Barclay JW, Robertson RM, Brown IR, Atwood HL (1999) Neuroprotection at Drosophila synapses conferred by prior heat shock. J Neurosci 19:4360–4369
40. Karunanithi S, Barclay JW, Brown IR, Robertson RM, Atwood HL (2002) Enhancement of presynaptic performance in transgenic Drosophila overexpressing heat shock protein Hsp70. Synapse 44:8–14. doi:10.1002/syn.10048
41. Kennedy D, Jager R, Mosser DD, Samali A (2014) Regulation of apoptosis by heat shock proteins. IUBMB Life 66:327–338. doi:10.1002/iub.1274
42. Khalouei S, Chow AM, Brown IR (2014) Localization of heat shock protein HSPA6 (HSP70B’) to sites of transcription in cultured differentiated human neuronal cells following thermal stress. J Neurochem 131:743–754. doi:10.1111/jnc.12970
43. Kiaei M, Kipiani K, Petri S, Chen J, Calingasan NY, Beal MF (2005) Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener Dis 2:246–254. doi:10.1159/000090364
44. Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L (2004) Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 10:402–405. doi:10.1038/nm1021
45. Kim DH, Shin EK, Kim YH, Lee BW, Jun JG, Park JH, Kim JK (2009) Suppression of inflammatory responses by celastrol, a quinone methide triterpenoid isolated from Celastrus regelii. Eur J Clin Investig 39:819–827. doi:10.1111/j.1365-2362.2009.02186.x
46. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ (2004) Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem 279:25497–25502. doi:10.1074/jbc.M400255200
47. Kroemer G et al (2009) Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16:3–11. doi:10.1038/cdd.2008.150
48. Labbadia J, Novoselov SS, Bett JS, Weiss A, Paganetti P, Bates GP, Cheetham ME (2012) Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain 135:1180–1196. doi:10.1093/brain/aws022
49. Lang AE (2010) Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med 16:1223–1226. doi:10.1038/nm.2220
50. Liu J, Shinobu LA, Ward CM, Young D, Cleveland DW (2005) Elevation of the Hsp70 chaperone does not effect toxicity in mouse models of familial amyotrophic lateral sclerosis. J Neurochem 93:875–882. doi:10.1111/j.1471-4159.2005.03054.x
51. Martin JB (1999) Molecular basis of the neurodegenerative disorders. N Engl J Med 340:1970–1980. doi:10.1056/NEJM199906243402507
52. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW Jr, Morris JC (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease. Neurology 56:127–129
53. Mattoo RU, Goloubinoff P (2014) Molecular chaperones are nanomachines that catalytically unfold misfolded and alternatively folded proteins. Cell Mol Life Sci 71:3311–3325. doi:10.1007/s00018-014-1627-y
54. Mayer MP (2013) Hsp70 chaperone dynamics and molecular mechanism. Trends Biochem Sci 38:507–514. doi:10.1016/j.tibs.2013.08.001
55. McGoldrick P, Joyce PI, Fisher EM, Greensmith L (2013) Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta 1832:1421–1436. doi:10.1016/j.bbadis.2013.03.012
56. McGonigle P, Ruggeri B (2014) Animal models of human disease: challenges in enabling translation. Biochem Pharmacol 87:162–171. doi:10.1016/j.bcp.2013.08.006
57. Milnerwood AJ, Raymond LA (2010) Early synaptic pathophysiology in neurodegeneration: insights from Huntington’s disease. Trends Neurosci 33:513–523. doi:10.1016/j.tins.2010.08.002
58. Morimoto RI (1993) Cells in stress: transcriptional activation of heat shock genes. Science 259:1409–1410
59. Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6:11–22. doi:10.1038/nrn1587
60. Nillegoda NB, Bukau B (2015) Metazoan Hsp70-based protein disaggregases: emergence and mechanisms. Front Mol Biosci 2:57. doi:10.3389/fmolb.2015.00057
61. Nillegoda NB et al (2015) Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation. Nature 524:247–251. doi:10.1038/nature14884
62. Noonan EJ, Place RF, Giardina C, Hightower LE (2007a) Hsp70B’ regulation and function. Cell Stress Chaperones 12:393–402
63. Noonan EJ, Place RF, Rasoulpour RJ, Giardina C, Hightower LE (2007b) Cell number-dependent regulation of Hsp70B’ expression: evidence of an extracellular regulator. J Cell Physiol 210:201–211. doi:10.1002/jcp.20875
64. Noonan E, Giardina C, Hightower L (2008a) Hsp70B’ and Hsp72 form a complex in stressed human colon cells and each contributes to cytoprotection. Exp Cell Res 314:2468–2476. doi:10.1016/j.yexcr.2008.05.002
65. Noonan EJ, Fournier G, Hightower LE (2008b) Surface expression of Hsp70B’ in response to proteasome inhibition in human colon cells. Cell Stress Chaperones 13:105–110. doi:10.1007/s12192-007-0003-3
66. Paris D et al (2010) Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease. J Neuroinflammation 7:17. doi:10.1186/1742-2094-7-17
67. Poppe L, Rue L, Robberecht W, Van Den Bosch L (2014) Translating biological findings into new treatment strategies for amyotrophic lateral sclerosis (ALS). Exp Neurol 262(Pt B):138–151. doi:10.1016/j.expneurol.2014.07.001
68. Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP (2015) Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol 55:353–371. doi:10.1146/annurev-pharmtox-010814-124332
69. Ramirez VP, Stamatis M, Shmukler A, Aneskievich BJ (2014) Basal and stress-inducible expression of HSPA6 in human keratinocytes is regulated by negative and positive promoter regions. Cell Stress Chaperones 20:95–107. doi:10.1007/s12192-014-0529-0
70. Richter K, Haslbeck M, Buchner J (2010) The heat shock response: life on the verge of death. Mol Cell 40:253–266. doi:10.1016/j.molcel.2010.10.006
71. Ross RA, Spengler BA (2007) Human neuroblastoma stem cells. Semin Cancer Biol 17:241–247. doi:10.1016/j.semcancer.2006.04.006
72. Salminen A, Lehtonen M, Paimela T, Kaarniranta K (2010) Celastrol: molecular targets of thunder god vine. Biochem Biophys Res Commun 394:439–442. doi:10.1016/j.bbrc.2010.03.050
73. Sarge KD, Murphy SP, Morimoto RI (1993) Activation of heat shock gene transcription by heat shock factor 1 involves oligomerization, acquisition of DNA-binding activity, and nuclear localization and can occur in the absence of stress. Mol Cell Biol 13:1392–1407
74. Sasaki E (2015) Prospects for genetically modified non-human primate models, including the common marmoset. Neurosci Res 93:110–115. doi:10.1016/j.neures.2015.01.011
75. Schafer DP, Stevens B (2015) Microglia function in central nervous system development and plasticity cold spring. Cold Spring Harb Perspect Biol 7:a020545. doi:10.1101/cshperspect.a020545
76. Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging 27:1372–1384. doi:10.1016/j.neurobiolaging.2005.09.012
77. Shankar GM, Walsh DM (2009) Alzheimer’s disease: synaptic dysfunction and Abeta. Mol Neurodegener 4:48. doi:10.1186/1750-1326-4-48
78. Sharma S et al (2015) Celastrol, an oral heat shock activator, ameliorates multiple animal disease models of cell death. Cell Stress Chaperones 20:185–201. doi:10.1007/s12192-014-0536-1
79. Sheikh S, Safia, Haque E, Mir SS (2013) Neurodegenerative diseases: multifactorial conformational diseases and their therapeutic interventions. J Neurodegener Dis 2013:563481. doi:10.1155/2013/563481
80. Shen HY, He JC, Wang Y, Huang QY, Chen JF (2005) Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 280:39962–39969. doi:10.1074/jbc.M505524200
81. Stephan AH, Barres BA, Stevens B (2012) The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci 35:369–389. doi:10.1146/annurev-neuro-061010-113810
82. t Hart BA, Abbott DH, Nakamura K, Fuchs E (2012) The marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease. Drug Discov Today 17:1160–1165. doi:10.1016/j.drudis.2012.06.009
83. Veloso AJ et al (2013a) Biological activity of sym-triazines with acetylcholine-like substitutions as multitarget modulators of Alzheimer’s disease. ACS Chem Neurosci 4:924–929. doi:10.1021/cn400028w
84. Veloso AJ et al (2013b) sym-Triazines for directed multitarget modulation of cholinesterases and amyloid-beta in Alzheimer’s disease. ACS Chem Neurosci 4:339–349. doi:10.1021/cn300171c
85. Veloso AJ et al (2014) Electrochemical immunosensors for effective evaluation of amyloid-beta modulators on oligomeric and fibrillar aggregation processes. Anal Chem 86:4901–4909. doi:10.1021/ac500424t
86. Venkatesha SH, Astry B, Nanjundaiah SM, Yu H, Moudgil KD (2012) Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines. Bioorg Med Chem 20:5229–5234. doi:10.1016/j.bmc.2012.06.050
87. Westerheide SD, Morimoto RI (2005) Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem 280:33097–33100. doi:10.1074/jbc.R500010200
88. Westerheide SD et al (2004) Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 279:56053–56060. doi:10.1074/jbc.M409267200
89. Wong KF, Yuan Y, Luk JM (2012) Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents. Clin Exp Pharmacol Physiol 39:311–320. doi:10.1111/j.1440-1681.2011.05586.x
90. Wu Y, Dissing-Olesen L, MacVicar BA, Stevens B (2015) Microglia: dynamic mediators of synapse development and plasticity. Trends Immunol 36:605–613. doi:10.1016/j.it.2015.08.008
91. Xiao C, Mileva-Seitz V, Seroude L, Robertson RM (2007) Targeting HSP70 to motoneurons protects locomotor activity from hyperthermia in Drosophila. Dev Neurobiol 67:438–455. doi:10.1002/dneu.20344
92. Yang L, Li Y, Ren J, Zhu C, Fu J, Lin D, Qiu Y (2014) Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2. Int J Mol Sci 15:13637–13648. doi:10.3390/ijms150813637
93. Zhang YQ, Sarge KD (2007) Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response. J Mol Med (Berl) 85:1421–1428. doi:10.1007/s00109-007-0251-9